PROactive: Summary

1
PROactive Summary

• Pioglitazone added to standard antidiabetic and
  CV therapies showed
• 10 RRR in primary outcome Composite
  all-cause mortality, nonfatal MI (including
  silent MI), stroke, ACS, leg amputation,
  coronary or leg revascularization
• 16 RRR in secondary outcome All-cause
  mortality, nonfatal MI (excluding silent MI) or
  stroke
• No difference between groups in HF mortality
• Continued divergence in survival
  curves Greater benefit with longer treatment
  duration hypothesized

PROactive results support use of PPAR? modulator
in patients with diabetes at high CVD risk May
improve CVD outcomes and need to add insulin
Dormandy JA et al. Lancet. 20053661279-89.